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Summary: Lipoprotein(a) levels in plasma are considered an independent risk factor for atherosclerosis at different
sites. Although Lp(a) measurements have recently gained interest in clinical laboratories, several problems are
still unresolved.
A potential source of pre-analytical variability lies in the treatment of the specimens, since it has been reported that
values of several lipid quantities are lower when measured in plasma instead of serum.
Lp(a) was measured in serum and in EDTA-treated, heparinised and citrated plasma from 15 healthy volunteers.
Four analytical methods were used: two enzyme linked immunosorbent assays [ELISA] based on a polyclonal anti-
apolipoprotein(a) antibody and a polyclonal anti-apolipoprotein B antibody, respectively; and two immunonephelo-
metric assays [INA] based on a N antiserum to Lp(a) and on three monoclonal antibodies adsorbed on latex
particles, respectively.
Our measured Lp(a) values in plasma were lower than those found in serum, in particular for EDTA-treated (anti-
apolipoprotein(a) ELISA: p < 0.01, anti-apolipoprotein B ELISA: p < 0.001 and Latex enhanced INA: p < 0.001)
and citrated plasma (anti-apolipoprotein(a) ELISA: p < 0.05, anti-apolipoprotein B ELISA: p < 0.001 and INA:
ρ < 0.001). Lp(a) values measured in heparinised plasma were also lower than those found in serum, but the
difference was not statistically significant.
Introduction
Lipoprotein(a) [Lp(a)] is a cholesterol-rich lipoprotein in
which the polymorphic glycoprotein apolipoprotein(a) is
covalently linked to apolipoprotein B 100, the main pro-
tein moiety of LDL (1).
Apolipoprotein(a) structure is closely related to plasmin-
ogen; its size polymorphism results from multiple re-
peats of the plasminogen-like kringle IV domain, which
give rise to 34 or more isoforms in plasma (2).
Since several studies have reported a strong correlation
between increased levels of Lp(a) in plasma and both
clinical and preclinical atherosclerosis (3—6), Lp(a)
measurements have recently gained popularity in clin-
ical laboratories.
The main problem in Lp(a) measurements arises from
the lack of a primary standard for secondary calibration
of the assays employed in Lp(a) analysis. Moreover, due
to the apolipoprotein(a) size polymorphism, the use of
polyclonal antibodies in immunpmetric commercial kits
recognising different apolipoprotein(a) domains often
results in discordant data among assays.
EDTA-plasma or serum are the preferred specimens for
Lp(a) assays but little is known about the effect of anti-
coagulants on Lp(a) measurements. Cooper et al. con-
sidered EDTA as the preferred anticoagulant for routine
analysis of lipoproteins and lipids since it is regarded as
more efficient both in preventing lipids oxidation and in
preserving the immunoreactivity of the particles (7). On
the other hand, it has been reported that values for total
cholesterol, triacylglycerols and high density lipopro-
tein-cholesterol, as measured with several analytical
methods, are significantly lower in plasma than in se-
rum (7, 8).
It has also been observed that Lp(a) values measured in
plasma are different from those found in serum; this hin-
ders the definition of the normal range of concentrations
among laboratories and comparisons in epidemiological
studies.
The aim of the present study was to compare results of
Lp(a) measurements in serum and plasma (EDTA-




Whole blood from 15 healthy volunteers was collected after one
night fasting in 8 ml evacuated tubes containing either no anticoag-
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ulant or alternatively disodium EDTA (final concentration 4.46
mmol/1), lithium-heparin (final concentration 143 IU/1), buffered
sodium citrate (final concentration 0.129 mol/1). Serum and plasma
were removed from cellular components by centrifuging at 3000
min"1 for 20 min. Samples were analysed within 2 h after veni-
puncture. Results obtained in EDTA and citrated plasma were ad-
justed for dilution.
Lp(a) concentration was measured with two enzyme linked immu-
nosorbent assays [ELISA] and with two immunonephelometric as-
says [INA].
Enzyme immunoassays
The first ELISA method (Macra Lp(a) - Terumo, Elkton, Ma,
USA) uses monoclonal anti-apolipoprotein(a) antibody coated
plates for capturing the Lp(a) particles and a second horseradish
peroxidase-conjugated anti-apolipoprotein(a) polyclonal antibody
for the detection.
All the samples were analysed in duplicate and the average value
was reported. Coefficients of variation (CVs) were respectively 3%
within-assay and 5% between-assay.
The second ELISA method (Innotest Lp(a) — Byk-Sangtec Diag-
nostica, Dietzenbach, Germany) uses monoclonal anti-apolipopro-
tein(a) antibody coated plates for capturing the Lp(a) particles and
a second horseradish peroxidase-conjugated polyclonal anti-apoli-
poprotein B antibody for the detection. All the samples were ana-
lysed in duplicate and the average value was reported. CVs were
respectively 4% within-assay and 5% between-assay.
Although the standard curves of both the assays range respectively
from 0 to 800 mg/1 and from 0 to 1000 mg/1 of Lp(a) concentration,
we arbitrarily chose dilutions of each sample in order to obtain
absorbance values in the middle part of the standard curve, thus
reducing the bias effect of high and low absorbances.
Immunonephelometr ic assays
The first INA was performed on a Behring Nephelometric Analyser
(BNA, Behringwerke, AG, Marburg, Germany) using a N antise-
rum to human Lp(a). Results were evaluated by means of logit-log
function of light scattering intensities vs. respective concentrations
of scalar dilutions of Lp(a) standard (N Lp(a) Standard - Behring).
The assay involves 1 : 5 dilution of the sample; each aliquot was
analysed in triplicate and the average value was reported.
The second ΕΝΑ was performed on BNA using three monoclonal
antibodies adsorbed on latex particles. Results were evaluated by
means of logit-log function of light scattering intensities vs. respec-
tive concentrations of scalar dilutions of Lp(a) standard (N Lp(a)
Standard - Behring). The assay involves 1 : 100 dilution of the
sample; each aliquot was analysed in duplicate and the average
value was reported.
All results were reported as Lp(a) total mass (mg/1).
Statistical evaluation
Non-parametric correlation was done according to Passing &
Bablok. Significance was calculated using Wilcoxon's matched-




Lp(a) values measured in anticoagulant-treated plasma
tend to be lower than those measured in serum (fig. 1).
In particular, results from EDTA and citrated plasma
(but not heparin-plasma) are significantly lower
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Fig. 1 Comparison of Lp(a) concentrations in serum and in
EDTA-treated, heparinised and citrated plasma, measured with an
ELISA employing a polyclonal anti-apolipoprotein(a) antibody.
Non-parametric properties of the curve and correlation coefficients
according to Passing & Bablok are:
y = 0.928x - 0.271 and r = 0.995 (a),
y = 0.983x + 4.96 and r = 0.986 (b),
y = 0.912x + 0.05 and r = 0.996 (c).
serum (tab. 1). Correlation coefficients between senim
and plasma are r = 0.995 for EDTA-treated, r = 0.986
for heparinised and r = 0.996 for citrated plasma,
respectively.
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Tab. 1 Statistical significance of Lp(a) concentrations determined
with four analytical methods in serum and in EDTA-treated, hepa-























Serum/ p < 0.05 p < 0.001 p < 0.001 n. s.
Citrate
Anti-apolipoprotein B ELISA
As shown in figure 2, Lp(a) values tend to be lower in
anticoagulated plasma than in serum. In particular re-
sults from EDTA and citrated plasma (but not heparin-
plasma) are significantly lower (p < 0.001 and
p < 0.001 respectively) than those from serum (tab. 1).
Correlation coefficients between serum and plasma are
r = 0.996 for EDTA-treated, r = 0.996 for heparinised
and r = 0.986 for citrated plasma, respectively.
Immunonephelometry
As shown in figure 3, only citrated plasma shows lower
Lp(a) values compared with those in serum (p < 0.001)
(tab. 1). Correlation coefficients between serum and
plasma are r = 0.986 for EDTA-treated, r = 1.000 for
heparinised and r = 0.994 for citrated plasma, respec-
tively.
Latex-enhanced immunonephelometry
As shown in figure 4, only EDTA plasma shows lower
Lp(a) values compared with those in serum (p < 0.001)
(tab. 1). Correlation coefficients between serum and
plasma are r = 0.996 for EDTA-treated, r = 0.986 for
heparinised and r = 0.989 for citrated plasma, respec-
tively.
Discussion
Lp(a) measurements have gained interest due to the re-
peatedly reported correlation between increased Lp(a)
concentrations in plasma and atherothrombotic diseases
(3-6).
The collection and treatment of specimens represent a
major source of inter-laboratory variation. It has been
reported that values of several lipids and lipoproteins
analysed with different methods are lower in EDTA and
citrated plasma than in serum (7, 8). The differences
persist after correction for dilution factors, and it has
been suggested that they may arise from a shift of water
from blood cells into plasma induced by the anticoagu-
lants.
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Fig. 2 Comparison of Lp(a) concentrations in serum and in
EDTA-treated, heparinised and citrated plasma, measured with an
ELISA employing a polyclonal anti-apolipoprotein B antibody.
Non-parametric properties of the curve and correlation coefficients
according to Passing & Bablok are:
y = 0.9 ί6χ - 2.554 and r = 0.996 (a),
y = 0.973x - 0.51 and r = 0.996 (b),
y = 0.874x -I- 0.86 and r = 0.986 (c).
In our study we compared the effects of three widely
used anticoagulants on Lp(a) measurements with four
commercial Lp(a) assays.
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Fig. 3 Comparison of Lp(a) concentrations in serum and in
EDTA-treated, heparinised and citrated plasma, measured with an
INA method employing a N antiserum to human Lp(a). Non-para-
metric properties of the curve and correlation coefficients accord-
ing to Passing & Bablok are:
y = 0.843x + 35.52 and r = 0.986 (a),
y = 0.966x + 8.51 and r = 1.00 (b),
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Fig. 4 Comparison of Lp(a) concentrations in serum and in
EDTA-treated, heparinised and citrated plasma, measured with a
latex-enhanced INA method employing three monoclonal antibod-
ies adsorbed on latex particles. Non-parametric properties of the
curve and correlation coefficients according to Passing & Bablok
are:
y = 0.916x + 1.826 and r = 0.996 (a),
y = 0.957x + 6.22 and r = 0.986 (b),
y = 0.834x + 10.90 and r = 0.989 (c).
Correlation coefficients between serum and plasma were In spite of the adjustment for dilutiqn, plasma Lp(a) val-
always good, and the assays always within the limits of ues always tended to be lower than those in serum. In
analytical variability. particular, values in EDTA-treated and citrated plasma
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were significantly lower (figs. 1, 2, 3 and 4) in three of
the four assays (tab. 1). Values in heparinised plasma
were also lower than in serum (figs. 1, 2, 3 and 4) but
the difference was not statistically significant (tab. 1).
It should be noted that the decrease of plasma Lp(a)
immunoreactivity in serum seems to parallel the pro-
gressive decrease of the anticoagulant concentration in
the sample, tending to be higher for citrated plasma (129
mmol/1 final concentration), intermediate for EDTA
plasma (4.46 mmol/1 final concentration) and lower for
heparinised plasma (1.2 mmol/1 final concentration). A
similar effect was observed after analysing apolipoprot-
ein A-I and apolipoprotein B in serum, heparinised and
EDTA-treated plasma from the same patients (unpub-
lished data). These observations may support the pro-
posal that water moves osmotically from the blood cells
into the plasma.
General agreement is still lacking concerning certain
theoretical and methodological aspects of the standard-
ization of lipoprotein(a) measurements. In this respect,
the exclusion of any possible source of pre-analytical
variability is a prerequisite to obtaining comparable re-
sults between laboratories employing different methods.
In our study Lp(a) values in plasma were generally
lower than those in serum; since agreement among
methods is satisfactory, as deduced by the correlation
coefficients, the effect of dilution can be safely forecast.
Moreover, when employing anticoagulants, the labora-
tory must be informed about the type of specimen in
order to consider a possible correction of results.
On the basis of the above precautions, we suggest that
serum or anticoagulant-treated plasma may both be used
in Lp(a) analysis.
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